The Cannabinoid CB₁ Receptor in Schizophrenia

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• The endocannabinoid system plays a role in brain function.
• Evidence suggests its involvement in schizophrenia pathophysiology.
• The cannabinoid CB1 receptor is a potential therapeutic target for schizophrenia.

Purpose of the Study:

• To systematically review evidence for CB1 receptor alterations in schizophrenia.
• To explore the role of CB1 receptor dysfunction in schizophrenia.
• To assess the therapeutic potential of targeting the CB1 receptor.

Main Methods:

• Systematic literature search of MEDLINE, EMBASE, PsycArticles, and PsycINFO.
• Inclusion of 8 preclinical and 16 clinical studies.
• Analysis of in vivo and ex vivo findings on CB1 receptor levels.

Main Results:

• Most preclinical studies (6/8) showed reduced CB1 receptors in schizophrenia models.
• Majority of in vivo clinical imaging studies (3/4) found reduced CB1 receptor availability.
• Ex vivo studies reported mixed findings: no change (5/11), increased (4/11), or decreased (2/11).

Conclusions:

• CB1 receptor alterations are consistently observed in schizophrenia.
• Methodological differences may explain discrepancies in ex vivo findings.
• CB1 receptor dysfunction contributes to schizophrenia pathophysiology and represents a therapeutic target.